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prior to and following the switch both in the intervention and the control groups.
CONCLUSIONS:The switch to a generic substitute in the case of rosiglitazone led to
a reduction in health care costs, without affecting patients’ health.
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OBJECTIVES: Diabetes affects more than 23 million Americans. Despite the impor-
tance of drug treatment, little is known about the level of the complexity of drug
therapy and its socio-economic variants in patients with diabetes. METHODS: we
analyzed 2,189 adult patients with diabetes aged 18-85 using a nationally represen-
tative sample in Medical Expenditure Panel Survey (MEPS) in 2007, which was
linked with the prescription medication claim files. Generalized linear models
(GLMs) were used to fit the distribution of drug spending to analyze the socio-
economic variants in drug spending, controlling for age, gender, race, geographic
regions, marital status, general health perception, and 8 comorbid conditions. All
analyses were weighted to reflect the complex sample design in MEPS. RESULTS:
The 2,189 adult diabetes patients represented 17.5 million diabetes patients and a
total of $79.5 billion spending on prescription drugs by diabetes patients in the US
in 2007. On average, a diabetes patient had 46 prescriptions, for a total of $4,235 of
total drug spending and $1,323 out-of-pocket spending. The top 5 leading drug
classes included antihyperlipidemic (13.4% of total drug spending), analgesics
(4.4%), and proton pump inhibitors (3.8%), ACE-inhibitors (3.7%), and antidepres-
sants (3.2%). On average, a diabetes patient used 3.52 (s.d. 1.76) classes of drugs
within the 10 drug classes with the highest spending. In multivariate regression
analyses, compared to those enrolled in the Medicare Part D prescription drug
program, those with no health insurance, with private insurance, and Medicaid
spent 73%, 44%, and 16% less in prescription drugs (p0.001, p0.001, p0.03,
respectively). Compared to non-Hispanic whites, the blacks spent 15% less on pre-
scription drugs (p0.05). CONCLUSIONS: The diabetes patients often used a mul-
tiple classes of drugs. Insurance coverage and races affect the drug spending, hold-
ing everything else constant. More researches are much needed to investigate the
consequences of such complexity.
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OBJECTIVES: Few studies have examined the effects of the Medicare Part D cover-
age gap onmedication behaviors for diabetic patients. Diabetes accounts for 32% of
the Medicare expenditure and 20% of the Medicare beneficiaries suffer from dia-
betes. The current study examined how entering the coverage gap in 2007 affected
medication adherence rates, medication consumption behavior and resource uti-
lization among Medicare Part D beneficiaries taking oral anti-diabetic medications
with different levels of cost-sharing. METHODS: The study used a longitudinal,
retrospective pre-post cohort design with a 5% national random sample of Medi-
care enrollees. Beneficiaries on oral anti-diabetic medications entering the cover-
age gap (n78,224)were identified using prescription drug records. Health resource
utilizationmeasureswere derived from inpatient, outpatient and carrier claims for
these beneficiaries. Adherence wasmeasured as proportion of days covered (PDC).
RESULTS: A total of 60.1 % of the beneficiaries entered the coverage gap and 20.3%
reached catastrophic coverage. The number of patients who discontinuedmedica-
tions after entering the gap was associated with level of cost sharing (31.1 % (full
copayment), 20-27% (partial copayment), 14.0% (no copayment), p  0.0001). 2.0 %
of the beneficiaries switchedmedications after entering the coverage gap. However
no association of switching medications with cost sharing was observed. When
examining beneficiaries entering the gap but not reaching catastrophic coverage,
level of cost sharingwas strongly associatedwith a drop in PDC ( (5.9% decrease (no
copayment), 17% decrease (partial copayment), 20.3% decrease (full copayment),
p 0.0001). CONCLUSIONS: Increased cost sharing after entering the coverage gap
was associated with negative changes in medication consumption behaviors (ad-
herence and continuation) among patients on oral anti-diabetic medications. The
findings demonstrate the importance of efforts to fill the coverage gap in the Medi-
care Part D program in order to ensuremore appropriatemedication use behaviors,
especially for beneficiaries with partial/full cost sharing.
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DECOMPOSING GENDER DIFFERENCES IN ANGIOTENSIN II CONVERTING
ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS AMONG
VETERANS WITH DIABETES
Sambamoorthi U1, Tiwari A2, Maney M2, Pogach L2
1West Virginia University, Morgantown, WV, USA, 2Department of Veterans Affairs, East
Orange, NJ, USA
OBJECTIVES: The objective of the study is to identify and measure the extent to
which gender differences in Angiotensin II Converting Enzyme Inhibitors (ACEI)
and Angiotensin Receptor Blockers (ARB) prescriptions could be explained by de-
mographic, socio-economic and health status factors. METHODS: Secondary data
analyses of merged Veteran Health Administration (VHA) and Medicare claims
data for the fiscal years 1997 through 2000. Diabetes was identified with Interna-
tional Classification of Diseases, 9th edition (ICD-9-CM) codes from inpatient or
outpatient physician visits over the 24 month period. The independent variables
were demographics, socio-economic characteristics, physical health and mental
health conditions. Based on the parameter estimates and distribution of individual
characteristics, we performed traditional and extended decomposition techniques
to analyze the drivers behind the gender differences in lipid control. Population
Studied: The final study sample consisted of 263,730 veterans who had an index
creatinine value in FY1999, and qualifying creatinine value between 90 and 365
days following. There were 5,458 women and 258,272 men veterans. RESULTS:
Overall, more men (58.1%) than women (51.3%) were prescribed ACEI/ARBs. Even
after controlling for many observable characteristics, women were less likely to
have ACEI/ARB prescriptions. The adjusted odds ratio was 0.82 with 95% CI  0.77,
0.87. Nearly one third of the 7 percentage point gap in prescription drug use was
explained by variables included in the model. The gender gap in ACEI/ARBs could
be explained by differences in indications for ACEI/ARB, diabetes severity, and
mental illness (depression, anxiety, and PTSD).CONCLUSIONS:Gender differences
in ACEI/ARB exist and only about one-third of the difference could be explained by
differences in patient characteristics. Mental health conditions may be a barrier to
lower ACEI/ARB rates among women. Our findings highlight the importance of
population health approach to medication use in terms of coordinated care for
mental illness and physical illnesses.
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OBJECTIVES: The decision to prescribe medication to newly diagnosed type 2 dia-
betic patients is influenced by subjective and objective factors including patients’
economic and social status. This study examines the relationship between social
and economic indicators and incident antidiabetic medication (ADM) prescribing
patterns. METHODS: A retrospective observational study identified newly diag-
nosed patients with type 2 diabetes from the 2007-2009 Kentucky Medicaid popu-
lation. Subjects were included if they had two diabetes-related non-complicated
claims with no claims prior to 2007 in the provider-claims file. Patients were strat-
ified into receiving an ADM 0-30 days following diagnosis and those receiving no
medicationwithin that time frame.We evaluated the effect of social and economic
factors on the pattern of prescribing. Mapping techniques were used to illustrate
county/regional ecological differences. RESULTS: Patients dispensed an ADMwere
significantly younger than those not dispensed a medication (43yo vs. 51yo;
P0.001). If patients were given an ADM, they were more likely prescribed met-
formin in the Appalachian and western rural counties compared with metropoli-
tan counties (39% vs. 32%; P0.044). Patients in urban counties were more often
dispensed insulin or two or more ADMs (44% vs. 40%; P0.136), however this was
not a significant difference. CONCLUSIONS: This study found younger patients
being prescribed an ADMwithin 30 days of incident diagnosis. Older patients were
more likely to have no medication after incident diagnosis or waiting for several
months before a medication is given. Patients in rural areas are more likely dis-
pensed metformin as the initial ADM. Multiple ADMs and insulin as the initial
medication may be a proxy measure for diabetes severity at first presentation.
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OBJECTIVES: Regional variation in healthcare spending is a long standing topic of
interest to health services research. Maturation of the Part D data affords us the
opportunity to examine this relationship with respect to drug spending and adher-
ence. Our objective is to determine if beneficiaries residing in regions characterized
by high Part D drug spending exhibit higher levels of utilization and adherence to
medications recommended in diabetes treatment guidelines. METHODS: We
tracked a random 5% sample of Medicare Part D enrollees diagnosed with diabetes
in 2006 and 2007 (N 236,321). Measures included averages for Part D spending, any
use, duration of therapy (DOT), and medication possession ratio (MPR) for oral
antidiabetic agents, ACE-inhibitors/ARBs, and antihyperlipidemic agents. We ag-
gregated individual values into metropolitan statistical areas (360) and rest-of-
state areas (48) and arrayed mean regional measures by deciles. We estimated
logistic and OLS regression models controlling for age, sex, comorbidity counts,
and decile ranking of drug spending in each beneficiary’s region of residence.
RESULTS: Part D drug spending varied by a factor of 1.89 between the lowest
($2,613) and highest ($4,952) spending deciles. After regression adjustments, the
ratio fell to 1.49.We found little geographic variation in prevalence of use andMPR.
However, DOT was roughly one month longer in each drug class in the top com-
pared to the bottom decile (p.001) in unadjusted comparisons. After adjustment,
differences in DOT range from 11-18 days longer for beneficiaries in the top spend-
ing decile (p.001). CONCLUSIONS:We found considerable geographic variation in
Part D drug spending. Almost half of the difference between the top and bottom
spending deciles could be attributed to differences in beneficiary age, sex, and
comorbidities. There were no significant regional differences in user rates or MPR,
but DOT for all three drug classes was significantly longer in high spending areas.
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OBJECTIVES: To evaluate the direct healthcare costs of type 2 diabetes (T2DM)
among older patients enrolled in Medicare Advantage plus prescription drug plan.
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METHODS: This retrospective cohort analysis utilized claims from a large national
health plan. Includedweremembers aged 65-89 years, with continuous enrollment
between Jan-2008 and Dec-2009. Patients with T2DM (cases) were propensity
matched 1:1 with non-diabetes patients (controls) by age, gender, ethnicity, geo-
graphic location, low-income status, and plan type. To assess burden of illness,
all-cause health care costs for 2009 were calculated as the sum of all medical and
pharmacy claims (based on ICD-9-CM and GPI codes), and were compared descrip-
tively for cases and controls. In addition, costs directly attributable to diabeteswere
evaluated for the case cohort (based on ICD-9-CM 250.xx and prescriptions for
anti-hyperglycemic agents). RESULTS: The analysis included 179,203 cases and
matched controls. There were no significant differences at baseline between co-
horts with respect to matched variables, however, cases had a significantly higher
mean (SD) Deyo-Charlson Comorbidity Index compared to controls (2.47 versus
0.77 respectively; p0.0001). Mean (SD) all-cause healthcare costs per patient per
year were significantly higher for cases versus controls for in-patient hospitaliza-
tion ($1,120$4,425 vs. $712$3,230), outpatient visits ($5,475$15,640 vs.
$3,620$11,149), office visits ($1,666$3,652 vs. $1,358$3,492), ER visits
($288$868 vs. $219$759), pharmacy costs ($2,195$2,807 vs. $1,342$2,438) and
total healthcare costs ($10,40619,959 vs. $6,993$14,836) respectively, all
p0.0001. The mean diabetes attributable total healthcare cost for the case cohort
was $3,588$9,270 per patient per year. CONCLUSIONS: All cause healthcare costs
were significantly higher for patients with T2DM than for matched controls, high-
lighting the serious burden of illness in this Medicare Advantage population.
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OBJECTIVES: Cushing’s disease (CD), a rare pituitary disorder, is associated with
significant morbidity and mortality, but the economic impact is unknown. This
study assessed the annual healthcare costs and utilization of CD patients.
METHODS: Administrative claims from 2004-2008 of a large population with com-
mercial or Medicare-supplemental insurance in the USwere analyzed. CD patients
were those with medical claims for Cushing’s syndrome (ICD-9-CM: 255.0) and
either benign pituitary adenoma (227.3) or hypophysectomy (07.6). Each CD patient
was age- and gender-matched to four patients with non-functioning pituitary ad-
enoma (NFPA) and ten population controls (PC). NFPA was identified as benign
pituitary adenoma without Cushing’s syndrome, acromegaly (253.0) or hyperpro-
lactinemia (253.1). Comorbid conditions and annual direct healthcare costs were
compared between cohorts by calendar year. RESULTS:The study identified 877 CD
patients (79% female; average age 43 years). Hypertension (43% [CD] vs. 24% [NFPA]
vs. 17% [PC]), diabetes (29% vs. 13% vs. 7%) and hyperlipidemia (27% vs. 21% vs. 14%)
were the most common comorbidities in CD patients and more prevalent than in
NFPApatients and PC (all p0.05). CD patients had significantly higher total health-
care costs than NFPA patients and PC in 2004-2008; the difference between cohorts
increased over time. In 2008, average healthcare costs were $26,440 among CD
patients, compared to $13,708 in NFPA patients and $5,954 in PC (both p0.05).
Approximately one-third of total costs among CD patients were attributable to
CD-related services. CD patients were more likely to have inpatient admissions
(20.7% vs. 15.8% [NFPA] vs. 7.1% [PC], both p0.01), had more frequent outpatient
hospital visits (6.5 vs. 3.8 vs. 1.8, both p0.01), and receivedmoremedications than
NFPA patients and PC (means: 10.0 vs. 7.4 vs. 4.7, both p0.01). CONCLUSIONS: CD
patients had more comorbidities than NFPA patients and PC, and incurred signif-
icantly higher annual healthcare costs.
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OBJECTIVES: Diabetes is a chronic disease that requires continuing care to reduce
the risk of long-term complications. In this sense it is important tomaintain a good
therapeutic arsenal providing good treatment to mantain type 2 diabetes (T2DM)
and hypertension under control, preventing complications. We decided to assess
the costs of the HIPERDIA program with medication provided by the government
for a future cost-effectiveness research. METHODS: HIPERDIA is a program for
monitoring hypertensive and diabetic patients under care in the public healthcare
system. Based on that database, we searched the number of patients under treat-
ment from 2005 to 2010 and also the number of doses of the drugs (glibenclamide
and metformin) available to control T2DM (Datasus/Hiperdia). Also, we looked at
the Brazilian price database (Banco de Preços) the minimum and the maximum
price paid by the government for those drugs to calculate their total costs in the
program. RESULTS: From 2002 to 2010, we found a total of 1,067,754 patients using
glibenclamide 5 mg and 662,519 patients under metformin 850 mg, however it was
not clear the number of patients taking both. The average dailydosewas 1.79 tablet
for glibenclamide and 1.74 for metformin. In the price database from the govern-
ment, we found that the average price paid for glibenclamide was R$ 0.008/daily
unit (ranging from R$ 0.007 to 0.04) and for metformin R$ 0.026/daily unit (ranging
from R$ 0.023 to 0.098). From January 2009 to August 2010 the total cost of this
programwith these 2 drugs reached R$ 1,567,145 and our projections showed that,
since 2002, the government spent about R$ 9 million. CONCLUSIONS: Generics
generated a huge price pressure for those drugs in Brazil and with this scenario it
seems to be difficult to predict the plans to update the drug list to provide more
effective treatments for this population.
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OBJECTIVES: This project presents an analysis of IT processes on variations of
prescribing patterns for patients diagnosedwith diabetes type II, following the first
study on electronic billing and its association with diabetic drug prescribing
(Huttin/Wong,2010).METHODS:A sample of 610 patients is extracted from the CDC
physician survey.IT processes include electronic medical records (EMR), with or
without patient demographics, computerized orders for Rx, tests, lab results, notes
from nurses and physicians, public health reporting. Several hierarchical cluster-
ing methods are tested to identify various stages of IT processes and the impact of
IT is analyzed with non parametric tests (analysis of variance) on prescribing
patterns. RESULTS: Two HB clustering methods (average method and ward) iden-
tify three clusters representing different stages of IT processes: physicians using no
IT at all (80.76%) and two levels of IT operations in practices (cluster 2: 17.33 %;
cluster 3: 1.91%). The dendogram with the AL method presents clearer separation
than the dendogram with the ward method. Variations in drug prescribing is sig-
nificant between clusters, using the scoring savage test:21 for cluster 1, 16.85 for
cluster 2, 4.4 for cluster 3 (P value 0.01). The analysis on new drugs does not show
different prescribing patterns; however, the number of injectables (insulin) per
patient is significantly higher in cluster 2 than 1 (0.51 verus 0.39). Different patterns
of IT processes are also identified within cluster 2 and other clustering methods
among grouping and similarity computations (e.g. Shusaku et als,2004)are tested to
analyze the propagation of IT processes among the practices of this dataset (gen-
eralisation tested with a similarity matrix). CONCLUSIONS: This project can be
used for analysis and management of IT processes inside clinical systems and
control for their effects on physician prescribing behaviours.Results confirm that in
addition to ebilling, different patterns of IT processes have an impact on treatment
regimens (especially affecting insulin or insulin/OAD combinations). This can com-
plement Koro et als study (2004).
PDB68
ASSESSING LIFEYEARS SAVED FROM 2000 TO 2010 IN CHINA DUE TO NOVO
NORDISK INSULIN
Henriksen O, Jain P, Nielsen OK
Novo Nordisk, Inc., Bagsvaerd, Denmark
OBJECTIVES: Insulin and other diabetes treatments are generally considered cost
effective treatment options as they reduce the incidence of complications, increase
life expectancy and improve quality of life. This paper quantifies in a new model
the life years saved in the Chinese diabetic population between 2000 and 2010 due
to sales of Novo Nordisk insulin.METHODS: The CORE diabetes model was used to
make projections of long-term survival rates for peoplewith type 2 diabetes treated
with defined therapies; modern insulin monotherapy (MI Mono), Modern Insulin
combined with Oral Anti Diabetics (OAD), human insulin combined with OAD (HI
OAD) and human insulin monotherapy (HI Mono). In the human insulin scenarios,
the base case cohort characteristics were based on the Chinese DiabCare data for
1998 (mean age 56.71 years, 58% male, duration of diabetes 7 years, HbA1c 8.81%).
The modern insulin scenarios (introduced around 2005) are based on cohort char-
acteristics observed in the Chinese PRESENT study (mean age 57.21 years, 51%
male, duration of diabetes 6 years, HbA1c 7.93%). Treatment effects in the four
interventions modelled; MI Mono, MI OAD, HI OAD and HI Mono relied on pub-
lished sources (HbA1c;1%,1.82%,1.2% and 0.7% respectively). The annual size
of the population treated was calculated using annual Novo Nordisk sales and
average daily insulin dosage as observed in the DiabCare China study. This process
was then repeated for each year from 2000 to 2010 making it possible to cumulate
the number of life years saved. RESULTS: The undiscounted life expectancy for the
4 different baseline cohortsmodelled in the CORE diabetesmodel was improved by
2.9, 2.7, 2.2, 1.7 forMIOAD,MIMono, HI OAD,HIMono respectively.CONCLUSIONS:
The cumulated undiscounted life years saved between 2000 and 2010 was esti-
mated at 136.198.66 due to treatment with Novo Nordisk insulin in China.
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OBJECTIVES: Exenatide and liraglutide are the two therapeutic options in the GLP-1
anti-diabetic medication class, to improve glycemic control in adults with type 2
diabetes (T2D). This study evaluated patient and prescriber characteristics, treat-
ment patterns, average daily dose (ADD), and glycemic control of patients initiating
GLP-1 medications in Germany. METHODS: The LifeLink™ EMR-EU database con-
tains records for over 15 million German patients and 3,000 physicians. The cohort
included patients who initiated exenatide or liraglutide during the index period
(01/01/2009 - 04/30/2010). Patients also had 180 days history, pre-index; 90-540
days follow-up, post-index; and a T2D diagnosis (ICD-10 E10-E14), pre-index. Uni-
variate tests were conducted at .05. RESULTS: The cohort included 692 patients
(exenatide 292, liraglutide 400): mean (SD) age 59 (10) years, 59%male. Diabetolo-
gists prescribed liraglutidemore frequently than exenatide (65% vs. 35%) compared
to non-diabetologists (51% vs. 49 %). Choice of GLP-1 was not associated with pa-
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